Literature DB >> 9038763

Granulocytic sarcoma with expression of CD30.

M Fickers1, P Theunissen.   

Abstract

A case of a young man with a spinal epidural tumour, initially diagnosed as large cell anaplastic malignant lymphoma, is reported. The tumour consisted of poorly differentiated cells showing immunoreactivity with antibodies directed against CD30 and CD45. Ten months later the patient developed acute myeloid leukaemia. The histological slides of the epidural tumour were reviewed, including additional enzymochemical and immunochemical stains. As the tumour showed immunoreactivity for myeloperoxidase and chloroacetate esterase, it was reclassified as a granulocytic sarcoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9038763      PMCID: PMC500728          DOI: 10.1136/jcp.49.9.762

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases.

Authors:  R J Penny; J C Blaustein; J A Longtine; G S Pinkus
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

2.  A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts.

Authors:  R Andreesen; J Osterholz; G W Löhr; K J Bross
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

3.  Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases.

Authors:  A Chott; K Kaserer; I Augustin; M Vesely; R Heinz; W Oehlinger; H Hanak; T Radaszkiewicz
Journal:  Am J Surg Pathol       Date:  1990-05       Impact factor: 6.394

4.  Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma.

Authors:  G Pallesen; S J Hamilton-Dutoit
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

5.  HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.

Authors:  W T Dalton; M J Ahearn; K B McCredie; E J Freireich; S A Stass; J M Trujillo
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

6.  Granulocytic sarcoma in nonleukemic patients.

Authors:  J M Meis; J J Butler; B M Osborne; J T Manning
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

7.  Extramedullary myeloid cell tumors. An immunohistochemical and morphologic study of 28 cases.

Authors:  S T Traweek; D A Arber; H Rappaport; R K Brynes
Journal:  Am J Surg Pathol       Date:  1993-10       Impact factor: 6.394

8.  Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.

Authors:  H Stein; J Gerdes; U Schwab; H Lemke; D Y Mason; A Ziegler; W Schienle; V Diehl
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

9.  Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases.

Authors:  R S Neiman; M Barcos; C Berard; H Bonner; R Mann; R E Rydell; J M Bennett
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860

  9 in total
  5 in total

1.  Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archival tissue.

Authors:  Leonard Hwan Cheong Tan; Elaine Do; Soo Yong Tan; Siew Meng Chong; Evelyn Siew Chuan Koay
Journal:  Mol Diagn       Date:  2004

Review 2.  Epidural myeloid sarcoma as the presenting symptom of chronic myeloid leukemia blast crisis.

Authors:  Maroua Slouma; Safa Rahmouni; Rim Dhahri; Yasmine Khayati; Samy Zriba; Wajdi Amorri; Imen Gharsallah; Leila Metoui; Bassem Louzir
Journal:  Clin Rheumatol       Date:  2020-05-26       Impact factor: 2.980

Review 3.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

4.  Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Authors:  Bin Li; Steven A Eschrich; Anders Berglund; Melissa Mitchell; David Fenstermacher; Hadi Danaee; Hongyue Dai; Daniel Sullivan; William L Trepicchio; William S Dalton
Journal:  JMIR Res Protoc       Date:  2017-03-20

5.  A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.

Authors:  Jeffrey P Sharman; Jennifer J Wheler; Lawrence Einhorn; Afshin Dowlati; Geoffrey I Shapiro; John Hilton; John M Burke; Tanya Siddiqi; Nancy Whiting; Shadia I Jalal
Journal:  Invest New Drugs       Date:  2019-04-16       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.